Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: Case report and review of the literature

Journal of Clinical Oncology

Volumn 34, Issue 4, 2016, Pages e21-e24

  Arce Salinas, Claudia ^a   Riesco Martinez, Maria Carmen ^b   Hanna, Wedad ^b   Bedard, Philippe ^c   Warner, Ellen ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; BICALUTAMIDE; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

BIOSYNTHESIS; BREAST NEOPLASMS; CASE REPORT; FEMALE; HUMAN; METABOLISM; MIDDLE AGED;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS;

EID: 84955440805     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.8899     Document Type: Article

References (34)

1. Perou C, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 206:747-752, 2000
2. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER) negative, progesterone receptor (PR) negative and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109:1721-1728, 2007
3. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
4. Dent R, Trudeau M, Pritchard KI, et al: Triple negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007
5. Perou C: Molecular stratification of triple-negative breast cancers. Oncologist 16:61-70, 2011 (suppl 1)
6. Metzger-Filho O, Tutt A, de Azambuja E, et al: Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30:1879-1887, 2012
7. Gucalp A, Gupta G, Patil S, et al: Androgen receptor (AR) expression in a cohort of patients with triple negative breast cancer. SABCS Symposium 2011, P4-02-04
8. Gucalp A, Traina TA: Triple negative breast cancer: Role of the androgen receptor. Cancer J 16:62-65, 2010
9. Ni M, Chen Y, Lim E, et al: Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20:119-131, 2011
10. Wirth MP, Hakenberg OW, Froehner M: Antiandrogens in the treatment of prostate cancer. E J Urol 51:306-314, 2007
11. Anderson J: The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 91:455-461, 2003
12. Pilepich MV, Winter K, John MJ, et al: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant of definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biophys 50:1243-1252, 2001
13. Liedtke C, Kiesel L: Current issues of targeted therapy in metastatic triple-negative breast cancer. Breast Care 6:234-239, 2011
14. Hudis CA, Gianni L: Triple negative breast cancer: An unmet medical need. Oncologist 16:1-11, 2011 (suppl 1)
15. Hickey TE, Robinson LL, Carroll JS, et al: Minireview: The androgen receptor in breast tissues - Growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26:1252-1267, 2012
16. Kotsopoulos J, Narod SA: Androgens and breast cancer. Steroids 77:1-9, 2012
17. Liao DJ, Dickson RB: Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80:175-189, 2002
18. Secreto G, Venturelli E, Meneghini E, et al: Testosterone and biological characteristics of breast cancers in postmenopausal women. Cancer Epidemiol Biomarkers Prev 18:2942-2948, 2009
19. Labrie F, Luu-The V, Labrie C, et al: Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152-182, 2003
20. Dimitrakakis C, Zhou J, Wang J, et al: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10:292-298, 2003
21. Isola JJ: Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 170:31-35, 1993
22. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, et al: Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer 52:581-584, 1992
23. Moinfar F, Okcu M, Tsybrovskyy O, et al: Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. Cancer 98:703-711, 2003
24. Ogawa Y, Hai E, Matsumoto K, et al: Androgen receptor expression in breast cancer: Relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431-435, 2008
25. Gonzalez LO, Corte MD, Vazquez J, et al: Androgen receptor expression in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 8:149, 2008
26. Niemeier LA, Dabbs DJ, Beriwal S, et al: Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23:205-212, 2010
27. Collins LC, Cole KS, Marotti JD, et al: Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health Study. Mod Pathol 24:924-931, 2011
28. Goldberg IS: Testosterone propionate therapy in breast cancer. JAMA 188:1069-1072, 1964
29. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al: Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15:2472-2478, 2009
30. Peters AA, Buchanan G, Ricciardelli C, et al: Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131-6140, 2009
31. Park S, Koo J, Park HS, et al: Expression of androgen receptors in primary breast cancer. Ann Oncol 21:488-492, 2010
32. Lehman BD, Bauer JA, Chen X, et al: Transcriptome analysis of triple negative breast cancer identifies six distinct biological subgroups and reveals therapeutic strategies. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr PD01-07)
33. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
34. Gucalp A, Tolaney SM, Isakoff SJ, et al: TBCRC 011: Targeting the androgen receptor (AR) in woman with AR+/ER-/PR- metastatic breast cancer (MBC). J Clin Oncol 30:50s, 2012 (suppl; abst 1006)